Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04939727 · ClinicalTrials.gov registry record · NA

Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0

A NA study of Opioid Use Disorder and Opioid Use, sponsored by HealthPartners Institute.

Completed
Registry status
NA
Development phase
115
Enrollment target
1
Study location

NCT04939727: Completed NA study of Opioid Use Disorder and Opioid Use, sponsored by HealthPartners Institute.

NCT04939727 is a NA study of Opioid Use Disorder and Opioid Use that has completed, run by HealthPartners Institute. The registered enrollment target is 115 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04939727, a NA study of Opioid Use Disorder and Opioid Use, has completed, sponsored by HealthPartners Institute.

COMPLETED
Registry status
NA
Development phase
115 participants
Enrollment target
1
Study location

Study Summary

This study integrates the Mental Health Research Network (MHRN) suicide risk models into Opioid Wizard, an electronic health record (EHR) clinical decision support (CDS) to identify and treat patients at high risk of opioid use disorder (OUD)/overdose or diagnosed with OUD, to alert primary care clinicians (PCCs) to patients at elevated risk for suicide and guide them through structured suicide risk assessment. In both intervention and control clinics, suicide risk scores will be calculated for all Opioid Wizard-eligible patients and relevant EHR data to inform analyses will be archived. In intervention clinics, Opioid Wizard will alert PCCs to Opioid Wizard-eligible patients who are at increased risk of suicide and coach them through use of the Columbia Suicide Severity Risk Scale (CSSRS), a structured tool in the EHR that will help PCCs assess immediate suicide risk. Based on the resulting CSSRS score, Opioid Wizard will provide EHR links for risk-based referrals and follow-up recommendations, including care as usual, routine or emergent referral to behavioral health, or transportation to the emergency department (ED) for further assessment. Primary outcome measures include completion of CSSRS assessments for at-risk patients and patient engagement in outpatient mental health care.

Primary Outcome

EHR documentation of a completed Columbia Suicide Severity Rating Scale (CSSRS) on the same day or in the 14 days following any outpatient visit during the observation period.

Interventions

  • OTHER OUD-CDS + Suicide Risk Model associated CDS

Study Locations (1)

Minnesota

  • HealthPartners Institute - Bloomington

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2021-08-03
Est. Completion 2022-07-31
Phase NA
HealthPartners Institute

146 total trials

What the finished NCT04939727 record still lists

NCT04939727 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which OUD-CDS + Suicide Risk Model associated CDS is the first listed.

NCT04939727 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04939727 about?

NCT04939727 is a clinical study titled "Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0". This study integrates the Mental Health Research Network (MHRN) suicide risk models into Opioid Wizard, an electronic health record (EHR) clinical decision support (CDS) to identify and treat patients at high risk of opioid use disorder (OUD)/overdose or diagnosed with OUD, to alert primary care cli...

What is the current status of trial NCT04939727?

This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2021-08-03. Estimated completion is 2022-07-31.

What conditions does trial NCT04939727 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Use, Suicide.

What interventions are being tested in trial NCT04939727?

The interventions under investigation include: OUD-CDS + Suicide Risk Model associated CDS (OTHER).

Who is sponsoring clinical trial NCT04939727?

This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04939727 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04939727's enrollment target sits among peer trials

115 124th of 257 higher than 134 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02346929 · 115 participants · NA

    Hematoma Block for Distal Radius Fracture

  • NCT03394365 · 115 participants · Phase 3

    A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

  • NCT03907475 · 115 participants · Phase 2

    Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

  • NCT05086692 · 115 participants · Phase 1

    A Beta-only IL-2 ImmunoTherapY Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04939727, the US trial registry maintained by the National Library of Medicine. NCT04939727 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.